



## Appendix C: Prescription Medication Table for Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) with Non-Valvular Atrial Fibrillation

Generic Name	Trade Name (formulation) (strengths)	Adults Doses	Approximate Cost per 30 days <sup>a</sup>	PharmaCare Coverage <sup>b</sup>
<b>Direct Thrombin Inhibitor<sup>1</sup></b>				
<b>dabigatran</b>	<b>Pradaxa<sup>®</sup></b> (capsule) (110, 150 mg)	150 mg BID OR 110 mg BID for patients with ≥ 1 of the following: <ul style="list-style-type: none"> <li>• Age ≥ 75 years</li> <li>• CrCl 30–50 mL/min</li> <li>• Concurrent use of strong P-glycoprotein inhibitors or platelet inhibitors</li> <li>• Previous GI bleed</li> </ul>	\$104	Special Authority  Limited Coverage
<b>Direct Factor Xa Inhibitors<sup>2,3</sup></b>				
<b>rivaroxaban</b>	<b>Xarelto<sup>®</sup></b> (tablet) (15, 20 mg)	20 mg PO once daily with food OR 15 mg PO once daily with food for patients with CrCL 30-49 mL/min	\$92	Special Authority  Limited Coverage
<b>apixaban</b>	<b>Eliquis<sup>®</sup></b> (tablet) (2.5, 5 mg)	5 mg PO BID OR 2.5 mg PO BID for patients with ≥ 2 of the following: <ul style="list-style-type: none"> <li>• Age ≥ 80 years</li> <li>• Body weight ≤ 60 kg</li> <li>• Serum creatinine ≥ 133 µmol/L</li> </ul>	\$104	Special Authority  Limited Coverage

**Abbreviations:** BID = twice daily; CrCl = creatinine clearance; GI = gastrointestinal; kg = kilogram; µmol/L = micromolar per litre; mg = milligram; mL/min = milliliter per minute; PO = taken orally.

**Note:** Please review product monographs at [hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php](http://hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php) and regularly review current Health Canada advisories, warnings and recalls at [www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/index\\_e.html](http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/index_e.html).

### Footnotes:

a Pricing is approximate as per PharmaNet 2014/08/20 and does not include dispensing fee.

b PharmaCare coverage is currently limited to patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism **AND** in whom anticoagulation is inadequate following at least a 2-month trial of warfarin **OR** for whom anticoagulation using warfarin is contraindicated or not possible due to inability to regularly monitor the patient via International Normalized Ratio (INR) testing (i.e., not access to INR testing services at a laboratory, clinic pharmacy, and at home). PharmaCare Coverage Definitions: **G:** generic(s) are available; **Regular Coverage:** also known as regular benefit; does not require Special Authority. Regular benefits may be fully or partially covered.\*; **Limited Coverage:** requires Special Authority for coverage. Limited Coverage benefits approved by Special Authority may be fully or partially covered.\*; **RDP:** Reference Drug Program. Drugs included in the RDP are comparable agents of the same therapeutic class. Patients receive full coverage of drugs designated as the Reference Drug(s) of the therapeutic class. Other drugs in the same RDP category are covered up to the price of the Reference Drug; **No coverage:** also known as non-benefit; does not fit the above categories.\* Note: Information on which products PharmaCare covers can be obtained using the B.C. PharmaCare Formulary Search ([www.health.gov.bc.ca/pharmacare/benefitslookup/](http://www.health.gov.bc.ca/pharmacare/benefitslookup/)). In all cases, coverage is subject to drug price limits set by PharmaCare and to the patient's PharmaCare plan rules and deductibles. See: [www.health.gov.bc.ca/pharmacare/plans/index.html](http://www.health.gov.bc.ca/pharmacare/plans/index.html) and [www.health.gov.bc.ca/pharmacare/policy.html](http://www.health.gov.bc.ca/pharmacare/policy.html) for further information.

### References:

1. Boehringer Ingelheim Canada Ltd. Product monograph Pradaxa (dabigatran etexilate) capsules [Internet]. 2013 [cited 2014 Mar 12].
2. Pfizer Canada Inc. Product monograph Eliquis (apixaban) tablets [Internet]. 2012 [cited 2014 Mar 12].
3. Bayer Inc. Product monograph Xarelto (rivaroxaban) tablet [Internet]. 2013 [cited 2014 Mar 14].